ClinicalTrials.gg
RecruitingNCT07949136Updated Nov 19, 2026

Discoid Excision Versus Segmental Resection for Rectal Endometriosis

An interventional study of Laparoscopic Discoid or Double Discoid Excision and Laparoscopic Segmental Rectal Resection in Rectal Endometriosis and Deep Infiltrating Endometriosis (DIE), sponsored by Alexandria University. Recruiting at 1 site in Egypt. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Alexandria University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 30 studies in Endometriosis with a site in Egypt — 5 open to participants now, 5 under way, none of them phase 3. Endometriosis · Egypt.

Planned enrollment
2nd of 25
200 · median 92
Started
2026
with 2 others
No phase
17 of 30
4 open now
Registered
30th of 30
by date
Lead sponsor
2 of 30
Alexandria University

Among the 30 studies in Endometriosis with a site in Egypt, this one is the 2nd largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2026, is one of 17 with no phase, and was the 30th registered.

Endometriosis

924 studies on the registry are indexed under Endometriosis; 269 are open to participants now.

Browse Endometriosis studies →

Open to participants now

5 of the 30 studies in Endometriosis with a site in Egypt are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 180 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 126 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Endometriosis with a site in Egypt, or all of them as a file.
02

Study summary

This clinical trial will compare two types of surgery for endometriosis affecting the rectum, the lower part of the bowel. It will include 200 women aged 18 to 45 years who have symptoms and a single area of rectal endometriosis smaller than 5 cm. All participants must need surgery and be suitable for either procedure.

The main questions are:

Do the two procedures differ in the risk of bowel complications within 90 days after surgery?

How do the procedures affect bowel function, quality of life, and pain?

Participants will be assigned by chance to one of two groups:

Discoid or double discoid excision: The surgeon removes one or two overlapping discs of the affected bowel wall without removing an entire bowel segment.

Segmental resection: The surgeon removes the affected bowel segment and joins the remaining bowel ends.

Both procedures will be performed using keyhole surgery. Assignment will take place during surgery, after the surgeon confirms that either procedure is suitable.

Researchers will compare bowel complications, including leakage from the bowel closure, narrowing of the rectum, and abnormal connections between the bowel and nearby organs or tissues. Participants will complete questionnaires about quality of life and bowel function before surgery and at 6 and 12 months afterward. Researchers will also assess pain, recovery, and the need for further surgery. Follow-up will continue for up to 24 months to assess later symptoms and further treatment.

Read the detailed description

This prospective, single-center, parallel-group randomized controlled trial will compare bowel-preserving discoid or double discoid excision with segmental rectal resection for symptomatic rectal deep endometriosis. The study focuses on women with a single rectal nodule smaller than 5 cm for whom both surgical approaches are considered technically feasible.

The rationale is to determine whether removing only the affected portion of the rectal wall offers a different balance of postoperative bowel complications and functional outcomes compared with removal of the affected bowel segment. The discoid excision arm includes a double discoid technique when the lesion cannot be removed using a single stapler application.

Participants will provide written informed consent before surgery. Randomization will occur intraoperatively after laparoscopic assessment confirms nodule characteristics and eligibility for both procedures. A computer-generated sequence will allocate participants in a 1:1 ratio. Allocation will be concealed through a centralized online system accessed by an independent trial coordinator.

The discoid excision group will undergo laparoscopic mobilization of the rectum and full-thickness removal of the lesion using a circular stapler. Sequential double discoid excision will be used when required by lesion size. The segmental resection group will undergo laparoscopic removal of the affected bowel segment with a stapled colorectal anastomosis. Both groups will follow standardized protocols for bowel closure integrity testing, selective pelvic drainage, and indications for a diverting stoma. Conversion from the assigned technique will be permitted when intraoperative findings make it necessary for patient safety.

Surgeons and participants will not be blinded to treatment allocation. Postoperative outcome assessors, complication assessors, and the statistician performing the primary analysis will be blinded to allocation.

The primary comparison will assess the occurrence of the composite bowel complication outcome within 90 days after surgery. Longer-term assessments will examine bowel function, endometriosis-related quality of life, pain, symptom recurrence, and reintervention. Quality of life and bowel function will be measured using the Endometriosis Health Profile-30 questionnaire and the Low Anterior Resection Syndrome score.

The primary analysis will follow the intention-to-treat principle. Prespecified adjustment variables will include nodule size, circumferential involvement, and distance from the anal verge. Repeated questionnaire measurements will be analyzed using mixed-effects models. Treatment-effect estimates will be reported with 95% confidence intervals.

03

Conditions studied

  • Rectal Endometriosis
  • Deep Infiltrating Endometriosis (DIE)

Browse trials for

Keywords

  • Deep Infiltrating Endometriosis
  • Bowel Endometriosis
  • Discoid Excision
  • Double Discoid Excision
  • Segmental Rectal Resection
  • Laparoscopic Surgery
  • Bowel Complications
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participants aged 18 to 45 years.
  • Symptomatic deep infiltrating endometriosis involving the rectum, confirmed by transvaginal or transrectal ultrasonography or pelvic magnetic resonance imaging.
  • A single rectal endometriosis nodule measuring less than 5 cm in maximum diameter and amenable to discoid or double discoid excision.
  • Indication for surgical management following failure of, to, or patient refusal of medical therapy.
  • The nodule is considered by the surgical team to be technically suitable for both discoid or double discoid excision and segmental rectal resection, based on its size, circumferential extent, and distance from the anal verge. Suitability for both procedures must be confirmed laparoscopically before randomization.
  • Ability to provide written .
  • Ability to complete patient-reported outcome questionnaires and comply with follow-up.

Exclusion criteria

Exclusion Criteria:

  • Rectal endometriosis nodule measuring 5 cm or larger in maximum diameter.
  • Rectal circumferential involvement exceeding 60%.
  • Multifocal bowel endometriosis.
  • Concurrent .
  • Inflammatory bowel disease.
  • Previous colorectal surgery.
  • Pregnancy.
  • Emergency presentation with bowel obstruction or perforation.
  • Inability to comply with follow-up or complete the required questionnaires.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Discoid or Double Discoid Excision

    Participants will undergo laparoscopic full-thickness discoid excision of the rectal endometriosis nodule using a circular stapler. When the nodule exceeds the capacity of a single stapler application, sequential double discoid excision will be performed using two circular staplers. The procedure will remove the affected rectal wall without segmental bowel resection.

    Procedure: Laparoscopic Discoid or Double Discoid Excision

  • Active comparator
    Segmental Rectal Resection

    Participants will undergo laparoscopic resection of the bowel segment affected by rectal endometriosis, followed by a stapled end-to-end or end-to-side colorectal anastomosis. Mesorectal preservation close to the bowel wall will be used to limit disruption of the local blood supply.

    Procedure: Laparoscopic Segmental Rectal Resection

Interventions

  • ProcedureLaparoscopic Discoid or Double Discoid Excision

    Laparoscopic mobilization of the rectum followed by full-thickness excision of the endometriosis nodule using a circular stapler. Sequential double discoid excision using two circular staplers will be performed when required by nodule size. An intraoperative air leak test will assess staple-line integrity. Pelvic drainage and a diverting stoma will be used selectively according to protocolized indications.

  • ProcedureLaparoscopic Segmental Rectal Resection

    Laparoscopic mobilization and resection of the affected bowel segment, followed by a stapled end-to-end or end-to-side colorectal anastomosis, with mesorectal preservation close to the bowel wall. An intraoperative air leak test will assess anastomotic integrity. Pelvic drainage and a diverting stoma will be used selectively according to protocolized indications.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Major Bowel-Related Complications

    Percentage of participants experiencing at least one of the following complications: anastomotic or staple-line leak, rectal stenosis, or rectovaginal or bowel fistula. Each participant will be counted once in the composite outcome, regardless of the number of qualifying complications. Complication severity will be graded using the Clavien-Dindo classification.

    Time frame: Within 90 days after surgery

Secondary outcomes

  1. Percentage of Participants With Anastomotic or Staple-Line Leak

    Percentage of participants developing leakage from the colorectal anastomosis or rectal staple line following the assigned surgical procedure. Complication severity will be graded using the Clavien-Dindo classification.

    Time frame: Within 90 days and within 12 months after surgery

  2. Percentage of Participants With Rectal Stenosis

    Percentage of participants developing postoperative narrowing at the rectal excision or colorectal anastomosis site. Complication severity will be graded using the Clavien-Dindo classification.

    Time frame: Within 90 days and within 12 months after surgery

  3. Percentage of Participants With Rectovaginal or Bowel Fistula

    Percentage of participants developing an abnormal communication between the rectum and vagina, or another postoperative bowel fistula. Complication severity will be graded using the Clavien-Dindo classification.

    Time frame: Within 90 days and within 12 months after surgery

  4. Endometriosis Health Profile-30 Domain Scores

    Endometriosis-related quality of life assessed using the Endometriosis Health Profile-30 (EHP-30). The core questionnaire measures five domains: pain, control and powerlessness, emotional well-being, social support, and self-image. Each domain is scored separately from 0 to 100, with higher scores indicating worse health status. Domain scores will be compared between groups over time.

    Time frame: Before surgery and at 6 and 12 months after surgery

  5. Low Anterior Resection Syndrome Score

    Bowel function assessed using the Low Anterior Resection Syndrome (LARS) score, which evaluates incontinence for flatus, incontinence for liquid stools, bowel movement frequency, clustering, and urgency. Total scores range from 0 to 42, with higher scores indicating worse bowel dysfunction. Categories are no LARS (0-20), minor LARS (21-29), and major LARS (30-42). Scores will be compared between groups over time.

    Time frame: Before surgery and at 6 and 12 months after surgery

  6. Operative Time

    Duration of the surgical procedure, measured in minutes.

    Time frame: During surgery

  7. Estimated Intraoperative Blood Loss

    Estimated volume of blood lost during the surgical procedure, measured in milliliters.

    Time frame: During surgery

  8. Postoperative Length of Hospital Stay

    Number of days from the surgical procedure to discharge from the hospital.

    Time frame: From surgery to discharge from the initial surgical hospitalization up to 1 week

  9. Percentage of Participants Receiving a Diverting Stoma

    Percentage of participants undergoing creation of a diverting stoma during the assigned surgical procedure.

    Time frame: During surgery

  10. Percentage of Participants With Recurrence of Endometriosis-Related Pain

    Percentage of participants experiencing recurrence of endometriosis-related pain symptoms after initial postoperative improvement.

    Time frame: At 12 and 24 months after surgery

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Apr 2027, 6 months after the start.

Of 199 non-industry interventional studies with no phase under Endometriosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 44. This study's planned 6 months is below that.

Counting every sponsor, half of 214 studies reached it within 25 months; a quarter within 13 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2026
First posted
Nov 19, 2026
StartActual
Oct 6, 2026
Primary completionEst.
Apr 2027
CompletionEst.
Jul 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07949136
Responsible party
Ahmed Mohi Eldein (Lecturer, Alexandria University) — Principal investigator
First posted
Nov 19, 2026
Start date
Oct 6, 2026
Primary completion
Apr 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Ahmed Mohi eldein, PhD
Contact
Ahmed.eldaoushy@alexmed.edu.eg
+201281362223

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion